Mustang Bio ( (MBIO) ) just unveiled an update.
Mustang Bio, Inc. faces potential delisting from Nasdaq as its stock price remains below $1.00 for over 30 days, though the company has been granted an extension to regain compliance by early 2025. Adding to the uncertainty, James Murphy resigned as Interim CFO, with CEO Manuel Litchman stepping in as his replacement. The company is exploring options to meet Nasdaq’s listing requirements but offers no guarantees of success.
For detailed information about MBIO stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
